ClinicalTrials.gg
CompletedNCT01658514Updated Dec 30, 2015Results posted

Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction

A Phase 2 interventional study of Met DR and Met XR in Renal Insufficiency, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-30.

Sponsored by Elcelyx Therapeutics, Inc. · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In addition, this study compared the behavior of a single dose of Met DR with that of extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney function described above.

02

Conditions studied

  • Renal Insufficiency

Browse trials for

03

In context

Renal Insufficiency

1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.

This study's enrollment of 39 is close to the median of 40 across 1,062 interventional studies indexed under Renal Insufficiency.

Browse Renal Insufficiency studies →

Lead sponsor

Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 80 (inclusive) years old at Visit 1 (Screening)
  2. Male, or female and met all of the following criteria:

    • Not breastfeeding
    • Negative pregnancy test result at Visit 1 (Screening) (not applicable to or surgically sterile females)
    • Surgically sterile, postmenopausal, or if of , practiced and was willing to continue to practice appropriate during the entire duration of the study
    • Body weight of ≥45 kg
  3. (BMI) of 18.0 to 40.0 kg/m² (inclusive) at Visit 1 (Screening)
  4. Had type 2 diabetes mellitus and an ≤10.0%
  5. Had a physical examination with no abnormalities as judged by the investigator
  6. Estimated (eGFR) ≥15 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation
  7. Ability to understand and willingness to adhere to protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Had End Stage Renal Disease requiring dialysis or severe renal dysfunction with \<15 mL/min/1.73 m²
  2. Was on dialysis or had been on dialysis within 12 months of Visit 1 (Screening)
  3. Had received or planned to receive any iodinated contrast dye within 1 week prior to Visit 1 (Screening) or after study medication administration
  4. Was taking or had taken within 1 week of Visit 1 cationic drugs that are eliminated by renal tubular secretion (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin)
  5. Had a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

    • Hepatic disease
    • Gastrointestinal disease
    • Endocrine disorder (type 2 diabetes mellitus was allowed)
    • Cardiovascular disease
    • Central nervous system diseases
    • Psychiatric or neurological disorders
    • Organ transplantation
    • Chronic or acute infection
    • Orthostatic hypotension, fainting spells or blackouts
    • Allergy or
  6. Had any chronic disease requiring medication that had been adjusted in the past 14 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)
  7. Had major surgery of any kind within 6 months of Visit 1 (Screening)
  8. Had a clinically significant finding of an (ECG) as assessed by the investigator at Visit 1 (Screening)
  9. Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities, other than those related to diabetes or renal disease and other stable diseases, judged by the investigator to be clinically significant at Visit 1 (Screening)
  10. Had a result \<8 g/dL or a level indicating severe anemia of renal origin
  11. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
  12. Had received Byetta® or short-acting insulin within 3 days of Visit 1 (Screening)
  13. Had received metformin within 4 weeks of Visit 1 (Screening)
  14. Had any drug treatment that affects gastrointestinal motility or gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid, within 2 days of Visit 2
  15. Abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
  16. Smoked more than 10 cigarettes, 3 cigars, or 3 pipes per day
  17. Had donated blood within 2 months of Visit 1 (Screening) or was planning to donate blood during the study
  18. Had received any drug within one month (or seven half-lives of the investigational drug, whichever was greater) of Visit 1 (Screening)
  19. Had known allergies or hypersensitivity to any component of study treatment
  20. Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Met DR

    One dose of 1000 mg metformin delayed-release

    Drug: Met DR

  • Active comparator
    Met XR

    One dose of 1000 mg metformin extended-release

    Drug: Met XR

  • Placebo comparator
    Placebo

    One dose of Placebo

    Drug: Placebo

Interventions

  • DrugMet DR

    metformin delayed-release tablets

  • DrugMet XR

    metformin extended-release tablets

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. AUC (0-t) of Plasma Metformin

    AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration

    Time frame: from the time of dosing (0 h) to 72 hours postdose

  2. Cmax of Plasma Metformin

    Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration

    Time frame: from the time of dosing (0 h) to 72 hours postdose

  3. Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration

    To determine the exposure-response relationship of metformin and plasma lactate concentrations

    Time frame: from the time of dosing (0 h) to 24 hours postdose

07

Results

Posted Dec 30, 2015

Participant flow

Participant flow — Overall Study
MilestoneSequence ABCSequence CABSequence BCA
Started141114
Completed treatment a141112
Completed treatment b131114
Completed treatment c131112
Started - normal rf cohort only323
Completed - normal rf cohort only323
Started - mild ri cohort only434
Completed - mild ri cohort only434
Started - moderate ri cohort only444
Completed - moderate ri cohort only342
Started - severe ri cohort only323
Completed - severe ri cohort only323
Completed131112
Not completed102
Withdrew: Protocol violation102

Outcome measures

PrimaryAUC (0-t) of Plasma Metformin

AUC (0-t) = Area under the curve from the time of dosing (0 h) to the time of the last quantifiable concentration following dose administration

Time frame:
from the time of dosing (0 h) to 72 hours postdose
Reported as:
Least squares mean · ng*h/mL
AUC (0-t) of Plasma Metformin
ng*h/mLMet DRMet XR
Normal (N = 8)5362 ± 94310411 ± 1831
Mild RI (N = 10)8705 ± 136811788 ± 1853
Moderate RI (N = 9)11477 ± 191520240 ± 3377
Severe RI (N = 7)22893 ± 430743683 ± 8218
Statistical analysis
  • Met DR vs Met XR · ANOVA · p = 0.0011 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 51.5 · 90% CI 37.77 to 70.23Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
  • Met DR vs Met XR · ANOVA · p = 0.0733 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 73.8 · 90% CI 55.97 to 97.43Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
  • Met DR vs Met XR · ANOVA · p = 0.0028 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 56.7 · 90% CI 42.25 to 76.10Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
  • Met DR vs Met XR · ANOVA · p = 0.0025 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 52.4 · 90% CI 37.61 to 73.02Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
PrimaryCmax of Plasma Metformin

Cmax = Maximum concentration from the time of dosing (0 h) to the time of the last quantifiable metformin concentration following dose administration

Time frame:
from the time of dosing (0 h) to 72 hours postdose
Reported as:
Least squares mean · ng/mL
Cmax of Plasma Metformin
ng/mLMet DRMet XR
Normal (N = 8)969 ± 1531479 ± 234
Mild RI (N = 10)1036 ± 1471340 ± 189
Moderate RI (N = 9)925 ± 1391634 ± 245
Severe RI (N = 7)1414 ± 2392590 ± 438
Statistical analysis
  • Met DR vs Met XR · ANOVA · p = 0.0474 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 65.5 · 90% CI 46.32 to 92.68Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
  • Met DR vs Met XR · ANOVA · p = 0.1691 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 77.3 · 90% CI 56.72 to 105.41Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
  • Met DR vs Met XR · ANOVA · p = 0.0064 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 56.6 · 90% CI 40.73 to 78.63Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
  • Met DR vs Met XR · ANOVA · p = 0.0097 (p-values \<0.10 are considered statistically significant) · % ratio of ls means: 54.6 · 90% CI 37.68 to 79.11Included treatment, renal group, sequence, period and treatment\*renal group as fixed effects and subject nested within sequence as a random effect.
PrimaryCorrelation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration

To determine the exposure-response relationship of metformin and plasma lactate concentrations

Time frame:
from the time of dosing (0 h) to 24 hours postdose
Reported as:
Number · R²
Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration
R²Met DRMet XR
Correlation of Placebo-adjusted Change From Pre-dose Value in Lactate Versus Metformin Concentration0.0000111290.069527
Statistical analysis
  • Met DR · Pearson Correlation · p = 0.9444 (R² for Placebo-adjusted Change from Pre-dose Value in Lactate Versus Metformin Concentration)
  • Met XR · Pearson Correlation · p = <0.0001 (R² for placebo-adjusted change from pre-dose value in lactate versus metformin concentration)

Adverse events

Collected over Approximately 19 to 76 days depending on the number of days before the start of Visits 2 and 3 and the number of washout days between the treatment visits.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/36 (0%)4/36 (11.1%)
Met DR—0/38 (0%)12/38 (31.6%)
Met XR—0/37 (0%)11/37 (29.7%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboMet DRMet XR
DiarrhoeaGastrointestinal disorders0/363/384/37
DizzinessNervous system disorders0/360/382/37
Vessel Puncture Site HaemorrhageGeneral disorders0/362/381/37
HyperglycaemiaMetabolism and nutrition disorders0/362/381/37
DyspepsiaGastrointestinal disorders1/361/381/37
ConstipationGastrointestinal disorders1/360/380/37
Food PoisoningGastrointestinal disorders1/360/380/37
HypoglycaemiaMetabolism and nutrition disorders1/360/380/37
Blood Creatine Phosphokinase IncreasedInvestigations1/360/380/37
NauseaGastrointestinal disorders0/361/381/37

Baseline characteristics

Randomized Population - All subjects were to receive all interventions and are distributed in this module according to their renal function cohort to inform PK analyses comparing these populations

Age, Continuous
Age, Continuous(years)NormalMild RIModerate RISevere RITotal
Mean54.5 ± 11.0160.8 ± 6.6272.6 ± 3.9070.5 ± 5.5065.1 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)NormalMild RIModerate RISevere RITotal
Female24017
Male6712732
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NormalMild RIModerate RISevere RITotal
Hispanic or Latino01203
Not Hispanic or Latino81010836
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NormalMild RIModerate RISevere RITotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00011
Black or African American152412
White7610326
More than one race00000
Unknown or Not Reported00000
Body Weight
Body Weight(kg)NormalMild RIModerate RISevere RITotal
Mean94.9 ± 18.0294.9 ± 12.0694.2 ± 14.9699.8 ± 10.6995.7 ± 13.73
BMI
BMI(kg/m²)NormalMild RIModerate RISevere RITotal
Mean32.8 ± 3.8131.8 ± 3.7930.4 ± 3.3333.3 ± 4.0931.9 ± 3.75
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bakris GL, Mudaliar, S, Kim T, Burns C, Skare S, Baron A, Fineman M. Effects of New Metformin Formulation in Stage 3 and 4 CKD: A Pilot Study. J Am Soc Nephrol. 2014; 25:549A.
  • DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9. PubMed 26773926 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2012
First posted
Aug 7, 2012
Start
Jan 2014
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Results first posted
Dec 30, 2015
Last update
Dec 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01658514
Lead sponsor
Elcelyx Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 7, 2012
Start date
Jan 2014
Primary completion
Jun 2014
Completion
Jun 2014
Results posted
Dec 30, 2015
Last update
Dec 30, 2015

Study contacts

George Canas, MD
principal investigator · Prism Research
Kenneth Lasseter, MD
principal investigator · Clinical Pharmacology of Miami, Inc
Alexander White, MD
principal investigator · Progressive Medical Research
Harold Bays, MD
principal investigator · Louisville Metabolic and Atherosclerosis Research Center
Craig Curtis, MD
principal investigator · Compass Research
Prabir Roy-Chaudhury
principal investigator · Cincinnati Veterans Affairs Medical Center Department of Internal Medicine
Sunder Mudaliar
principal investigator · San Diego Veterans Healthcare System
Nelson Kopyt
principal investigator · Northeast Clinical Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion